Sonnet BioTherapeutics Sets Virtual Annual Meeting for Sept 26
| Field | Detail |
|---|---|
| Company | Sonnet Biotherapeutics Holdings, Inc. |
| Form Type | DEF 14A |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $9,500, $2 Billion, $1 Billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: DEF 14A, Proxy Statement, Corporate Governance, Director Election, Executive Compensation, Auditor Ratification, Virtual Meeting, Shareholder Vote, Biotechnology, SEC Filing
TL;DR
**Sonnet's upcoming virtual annual meeting is a routine governance check, but keep an eye on director elections and say-on-pay for any shifts in investor sentiment or board dynamics.**
AI Summary
Sonnet BioTherapeutics Holdings, Inc. is holding its Annual Meeting of Stockholders on September 26, 2025, virtually, to address several key corporate governance matters. Stockholders will vote to elect five directors to the Board, including current Interim CEO Raghu Rao and CFO Donald Griffith, who have both served since 2020. The company is also seeking advisory approval for executive compensation for its Named Executive Officers and an advisory vote on the frequency of future 'say-on-pay' votes, with the Board recommending a three-year frequency. Additionally, stockholders will ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025. As of the record date, August 26, 2025, there were 6,827,352 shares of common stock outstanding, each entitled to one vote. The company has engaged Alliance Advisors, LLC for proxy solicitation, with a fee not expected to exceed $9,500.
Why It Matters
This DEF 14A filing outlines critical governance decisions for Sonnet BioTherapeutics, directly impacting investor confidence and strategic direction. The election of five directors, including key executives, will shape the company's leadership and future initiatives in a competitive biotech landscape. Advisory votes on executive compensation and its frequency provide stockholders a voice on management incentives, potentially influencing long-term performance and accountability. The ratification of KPMG LLP ensures continued financial oversight, crucial for maintaining transparency and trust among investors and regulators in the volatile biotechnology sector.
Risk Assessment
Risk Level: low — The filing primarily details routine corporate governance matters such as director elections, executive compensation advisory votes, and auditor ratification. There are no immediate financial or operational risks disclosed, nor any contentious proposals that suggest significant shareholder dissent or strategic shifts. The engagement of Alliance Advisors, LLC for proxy solicitation at a fee not exceeding $9,500 is a standard practice for annual meetings.
Analyst Insight
Investors should review the director nominees' backgrounds and the executive compensation details to ensure alignment with long-term company strategy. Participate in the virtual meeting on September 26, 2025, to cast votes on these governance items, particularly the 'say-on-pay' frequency, to influence future executive accountability.
Key Numbers
- September 26, 2025 — Annual Meeting Date (Date stockholders will vote on key proposals)
- 9:00 a.m. Eastern Time — Annual Meeting Time (Start time for the virtual Annual Meeting)
- August 26, 2025 — Record Date (Date for determining stockholders entitled to vote)
- 6,827,352 — Shares Outstanding (Number of common shares entitled to vote as of record date)
- 5 — Directors to be Elected (Number of directors standing for election to the Board)
- 2020 — Raghu Rao's Tenure Start (Year Interim CEO Raghu Rao began serving as a Director)
- 2020 — Donald Griffith's Tenure Start (Year CFO Donald Griffith began serving as a Director)
- 3 years — Recommended Say-on-Pay Frequency (Board's recommendation for how often to seek advisory approval of executive compensation)
- 1/3 — Quorum Requirement (Fraction of voting power required for a quorum at the Annual Meeting)
- $9,500 — Alliance Advisors Fee (Maximum expected fee for proxy solicitation services)
Key Players & Entities
- Sonnet BioTherapeutics Holdings, Inc. (company) — Registrant
- Raghu Rao (person) — Interim Chief Executive Officer and Director
- Donald Griffith (person) — Chief Financial Officer and Director
- Nailesh Bhatt (person) — Director
- Albert Dyrness (person) — Director
- Lori McNeill (person) — Director
- KPMG LLP (company) — Independent Registered Public Accounting Firm
- Alliance Advisors LLC (company) — Proxy Solicitation Firm
- Securities Transfer Corporation (company) — Transfer Agent
- $9,500 (dollar_amount) — Maximum fee for proxy solicitation services
FAQ
What is the purpose of Sonnet BioTherapeutics' upcoming Annual Meeting?
The Annual Meeting of Sonnet BioTherapeutics Holdings, Inc. on September 26, 2025, is being held to elect five directors, approve executive compensation on an advisory basis, vote on the frequency of future 'say-on-pay' proposals, and ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
When and where will Sonnet BioTherapeutics' Annual Meeting be held?
Sonnet BioTherapeutics' Annual Meeting will be held virtually via the Internet on Friday, September 26, 2025, at 9:00 a.m. Eastern Time. Stockholders can access the meeting at https://web.viewproxy.com/sonn/2025 after registering.
Who are the director nominees for Sonnet BioTherapeutics?
The five director nominees for Sonnet BioTherapeutics are Raghu Rao (Interim Chief Executive Officer), Donald Griffith (Chief Financial Officer), Nailesh Bhatt, Albert Dyrness, and Lori McNeill. All are current directors standing for re-election.
What is the record date for voting at Sonnet BioTherapeutics' Annual Meeting?
The record date for determining stockholders entitled to vote at Sonnet BioTherapeutics' Annual Meeting is the close of business on August 26, 2025. As of this date, there were 6,827,352 shares of common stock outstanding.
What is the Board's recommendation for the 'say-on-pay' frequency proposal for Sonnet BioTherapeutics?
The Board of Directors for Sonnet BioTherapeutics recommends that stockholders vote for a three-year frequency for seeking advisory approval of the compensation paid to its Named Executive Officers.
Which accounting firm is Sonnet BioTherapeutics proposing to ratify?
Sonnet BioTherapeutics is proposing to ratify the appointment of KPMG LLP as its independent registered public accounting firm for the fiscal year ending September 30, 2025.
How can Sonnet BioTherapeutics stockholders vote their shares?
Sonnet BioTherapeutics stockholders can vote electronically via the Internet at www.FCRvote.com/SONN, by telephone at 1-866-402-3905, by mail using the proxy card, or by attending the virtual Annual Meeting and voting electronically.
What constitutes a quorum for Sonnet BioTherapeutics' Annual Meeting?
A quorum for Sonnet BioTherapeutics' Annual Meeting requires the presence, in person or by proxy, of the holders of one-third of the voting power of the issued and outstanding shares of common stock entitled to vote on the record date, August 26, 2025.
What is a 'broker non-vote' and how does it affect Sonnet BioTherapeutics' proposals?
A 'broker non-vote' occurs when a broker cannot vote on a 'non-routine' matter without instructions from the beneficial owner. Proposals 1, 2, and 3 (director elections, say-on-pay, say-on-pay frequency) are generally non-routine, meaning broker non-votes will not affect their outcome. Proposal 4 (auditor ratification) is routine, so brokers may vote without instructions.
What are the costs associated with proxy solicitation for Sonnet BioTherapeutics?
Sonnet BioTherapeutics will pay all expenses for proxy solicitation. They have engaged Alliance Advisors, LLC for assistance, with a services fee not expected to exceed $9,500. The company will also reimburse brokers for reasonable out-of-pocket expenses.
Industry Context
Sonnet BioTherapeutics operates in the biotechnology sector, focusing on developing novel therapeutics. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Success often depends on innovation, clinical trial outcomes, and securing substantial funding for ongoing research and commercialization efforts.
Regulatory Implications
As a biotechnology company, Sonnet BioTherapeutics is subject to stringent regulations from bodies like the FDA. The success of its product candidates hinges on navigating complex clinical trial processes and obtaining regulatory approvals. Any delays or failures in these processes can have a material impact on the company's financial health and future prospects.
What Investors Should Do
- Review the proxy materials carefully before the September 26, 2025 Annual Meeting.
- Vote your shares, either in person (virtually) or by proxy.
- Consider the recommended frequency for 'say-on-pay' votes.
Key Dates
- 2025-09-26: Annual Meeting of Stockholders — Stockholders will vote on director elections, executive compensation, and ratification of the accounting firm.
- 2024-08-26: Proxy materials made available to stockholders — Marks the start of the period for stockholders to review information and cast their votes.
- 2025-09-30: Fiscal Year End — The period for which the independent auditor is being ratified and for which financial results will be reported.
Glossary
- DEF 14A
- A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of stockholders, including proposals to be voted on. (This document is the proxy statement for Sonnet BioTherapeutics Holdings, Inc.'s 2025 Annual Meeting.)
- Say-on-Pay
- A shareholder advisory vote on executive compensation. (Stockholders will vote on the executive compensation of Named Executive Officers and the frequency of future say-on-pay votes.)
- Named Executive Officers (NEOs)
- The top executive officers of a company whose compensation is disclosed in proxy statements. (The executive compensation for these individuals is subject to an advisory vote.)
- Independent Registered Public Accounting Firm
- An external audit firm hired by a company to conduct an independent audit of its financial statements. (KPMG LLP is being proposed for ratification as the company's auditor for the fiscal year ending September 30, 2025.)
- Proxy Solicitation
- The process by which a company requests that its shareholders grant authority to vote their shares in a specific way. (Alliance Advisors, LLC is engaged to assist in soliciting proxies for the annual meeting.)
Year-Over-Year Comparison
This filing is for the 2025 Annual Meeting, with proxy materials made available around August 26, 2024. The previous year's filing would have been for the 2024 Annual Meeting. Specific comparative financial metrics like revenue growth or margin changes are not detailed within this excerpt, which focuses on the upcoming meeting's agenda and governance proposals.
Filing Stats: 4,864 words · 19 min read · ~16 pages · Grade level 11.2 · Accepted 2025-08-26 17:01:29
Key Financial Figures
- $9,500 — es fee, which is not expected to exceed $9,500. We will also, upon request, reimburs
- $2 Billion — companies with total revenues exceeding $2 Billion. As the Chairman & President of InfoZen
- $1 Billion — to July 2008, Mr. Rao has managed over $1 Billion in U.S. Federal Government contracts. M
Filing Documents
- formdef14a.htm (DEF 14A) — 433KB
- formdef14a_001.jpg (GRAPHIC) — 40KB
- formdef14a_002.jpg (GRAPHIC) — 32KB
- proxy_001.jpg (GRAPHIC) — 464KB
- proxy_002.jpg (GRAPHIC) — 310KB
- 0001641172-25-025558.txt ( ) — 3155KB
- sonn-20240929.xsd (EX-101.SCH) — 6KB
- sonn-20240929_def.xml (EX-101.DEF) — 9KB
- sonn-20240929_lab.xml (EX-101.LAB) — 64KB
- sonn-20240929_pre.xml (EX-101.PRE) — 42KB
- formdef14a_htm.xml (XML) — 90KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 19 PAY VERSUS PERFORMANCE 20 TRANSACTIONS WITH RELATED PERSONS 23 PROPOSAL 2: SAY-ON-PAY 24 PROPOSAL 3: SAY-ON-PAY FREQUENCY 25 PROPOSAL 4: TO RATIFY THE APPOINTMENT OF OUR REGISTERED PUBLIC ACCOUNTING FIRM 26 STOCKHOLDER PROPOSALS 27 ANNUAL REPORT 27 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 27 OTHER MATTERS 27 SONNET BIOTHERAPEUTICS HOLDINGS, INC. PROXY FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS GENERAL INFORMATION This proxy statement contains information related to the Annual Meeting of Stockholders to be held on Friday, September 26, 2025 at 9:00 a.m. Eastern Time (the "Annual Meeting"). We are planning to hold the Annual Meeting virtually via the Internet, or at such other time and place to which the Annual Meeting may be adjourned or postponed. In order to attend our Annual Meeting, you must log in to https://web.viewproxy.com/sonn/2025 using the password provided to you after registration. Attendees will need to register prior to the meeting in order to receive access to the meeting. Proxies for the Annual Meeting are being solicited by our Board of Directors (the "Board"). This proxy statement is first being made available to stockholders on or about August 26, 2024. Important Notice of Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on September 26, 2025. Our proxy materials including our Notice of Internet Availability of Proxy Materials, Proxy Statement for the 2025 Annual Meeting, our annual report for the fiscal year ended September 30, 2024 and proxy card are available on the Internet at https://web.viewproxy.com/sonn/2025. Under SEC rules, we are providing access to our proxy materials both by sending you this full set of proxy materials and by notifying you of the availability of our proxy materials on the Internet. In this Proxy Statement, the terms the "Company," "we," "us," and "our" re